Esophageal metastasis is a secondary malignant tumor spread from another primary cancer to the esophagus via hematogenous, lymphatic, or direct invasion routes. In autopsy series, metastatic esophageal involvement is reported up to 6%, but clinically symptomatic metastasis is rare. Most common primary sources are lung, breast, melanoma, stomach, and kidney cancers. Three spread mechanisms exist: (1) hematogenous — submucosal nodules, (2) direct invasion — from mediastinal tumors, (3) lymphatic — compression or invasion through periesophageal lymphadenopathy. On imaging, it typically presents as eccentric submucosal mass, extrinsic compression, or focal wall thickening. When primary tumor history is known, diagnosis is usually straightforward; when unknown, it may be confused with primary carcinoma.
Age Range
40-80
Peak Age
60
Gender
Equal
Prevalence
Rare
Hematogenous metastasis is the most common mechanism — primary tumor cells reach the esophagus's rich submucosal vascular plexus through blood circulation and lodge there, forming submucosal nodules. Mucosa is initially intact (unlike primary carcinoma) but growing nodules may ulcerate the mucosa, creating 'bull's-eye' lesion — this pathognomonic finding describes a round submucosal mass with central ulceration. Direct invasion occurs when mediastinal tumors (lung, thyroid carcinoma) or large mediastinal lymphadenopathy breach the esophageal adventitia and grow into the wall — this mechanism creates eccentric wall thickening and extrinsic compression pattern. Lymphatic spread occurs through periesophageal lymph nodes enlarging and compressing or invading the esophageal wall. Enhancement pattern on CT reflects the primary tumor's vascularity — hypervascular metastases (melanoma, RCC, thyroid) show prominent arterial enhancement, while hypovascular metastases (breast, lung adenocarcinoma) enhance less. FDG uptake on PET-CT reflects the primary tumor's metabolic activity.
Round submucosal mass with central ulceration — pathognomonic metastasis finding on barium or CT. Tumor cells arriving hematogenously form submucosal nodule, the apex of the growing nodule ulcerates due to mucosal ischemia creating peripherally raised lesion with central depression. This pattern is most commonly seen in melanoma metastasis.
Eccentric submucosal mass or focal wall thickening in the esophageal wall on CT. Enhancement pattern varies by primary tumor: melanoma and RCC metastases enhance intensely, while breast and lung adenocarcinoma metastases enhance mildly. Since the mass is submucosal, mucosa is usually preserved — but central ulceration may develop in large lesions. May have smooth or lobulated margins.
Report Sentence
Eccentric enhancing submucosal mass measuring approximately ___ cm in the esophageal wall; in the context of known ___ carcinoma, consistent with metastasis.
Extrinsic compression or direct invasion of the esophagus by mediastinal tumor or large lymphadenopathy. Lung carcinoma, thyroid carcinoma, or mediastinal lymphadenopathy are the most common causes. On CT, esophageal lumen is narrowed, fat planes are obliterated, and tumor-esophagus interface is indistinct. In direct invasion, enhancing tumor tissue within the wall is observed.
Report Sentence
Extrinsic compression and possible direct invasion of the esophagus from mediastinal mass/lymphadenopathy with obliterated peritumoral fat planes; consistent with secondary esophageal involvement.
Submucosal metastatic mass shows variable signal on T2-weighted sequence — signal pattern depends on primary tumor histology. Melanoma metastasis may show low T2 signal (high T1) due to paramagnetic melanin content. RCC metastasis may contain cystic/necrotic component and show T2 hyperintensity. Breast carcinoma metastasis generally shows intermediate T2 signal. The tumor's relationship with esophageal wall and invasion depth are well evaluated on T2.
Report Sentence
Submucosal mass showing ___ signal on T2 in the esophageal wall; in the context of known ___ carcinoma, consistent with metastasis.
Focal FDG uptake in the esophageal wall on PET-CT. Uptake intensity reflects the primary tumor's metabolic activity — tumors with high FDG uptake (lung SCC, melanoma) show prominent uptake, while low-uptake tumors (prostate, some breast) may show milder uptake. PET-CT is superior in detecting simultaneous metastases in other organs. Differentiation from physiological esophageal FDG uptake (esophagitis, swallowing artifact) requires careful evaluation.
Report Sentence
Focal FDG uptake with SUVmax ___ in the esophageal wall; in the context of known ___ carcinoma, consistent with metastasis.
Characteristic hyperintense signal on T1-weighted sequence in melanoma metastasis — resulting from paramagnetic effect of melanin pigment. This finding is quite specific to melanoma metastasis and is a critical clue for differentiation from other primary/secondary tumors. T1 hyperintensity may not be seen in amelanotic melanoma. On T2, melanoma typically shows hypointense or intermediate signal — 'T1 bright, T2 dark' combination is pathognomonic for melanoma.
Report Sentence
Hyperintense signal on T1 and hypointense signal on T2 in esophageal submucosal mass, suggesting melanoma metastasis consistent with melanin content.
Prominently enhancing submucosal nodule in arterial phase — suggests hypervascular primary tumor metastasis (melanoma, RCC, thyroid carcinoma). Nodule is usually well-defined, round-oval shaped, and sharply demarcated from the esophageal wall. Multiple nodules may be seen (widespread hematogenous spread). This arterial hypervascular pattern is rare in primary esophageal carcinoma (SCC or adenocarcinoma).
Report Sentence
Prominently enhancing submucosal nodule in arterial phase in the esophageal wall; consistent with hypervascular metastasis.
Criteria
Spread via blood circulation. Most common from melanoma, RCC, breast, and lung carcinoma. Focal submucosal nodules, may be multiple.
Distinct Features
Round-oval submucosal nodules on CT, mucosa usually intact. Bull's-eye lesion characteristic. Enhancement variable depending on primary tumor. Multiple organ metastases accompany.
Criteria
Adjacent mediastinal tumor breaching adventitia and growing into wall. Lung carcinoma, thyroid carcinoma, thymic tumors most common sources.
Distinct Features
Fat plane between esophagus and mediastinal mass obliterated on CT. Eccentric wall thickening. Luminal narrowing may be prominent. Tumor tissue shows continuity within wall.
Criteria
Periesophageal lymph nodes enlarging to compress or invade esophageal wall. Stomach, lung carcinoma most common sources.
Distinct Features
Wall thickening on background of periesophageal lymphadenopathy on CT. Combination of extrinsic compression and intramural invasion. Continuity between nodal mass and wall thickening.
Distinguishing Feature
Primary SCC is mucosal origin with circumferential growth; metastasis is submucosal or extrinsic and usually eccentric. Mucosal destruction prominent in SCC; mucosa may be preserved in metastasis. Known primary tumor history and multiple organ involvement expected in metastasis.
Distinguishing Feature
GIST originates from muscularis propria and is T2 hyperintense; metastasis originates from submucosal vascular plexus and T2 signal varies by primary tumor. GIST is c-KIT positive; metastasis shows primary tumor's immunohistochemical profile. GIST usually solitary; metastasis may be multiple.
Distinguishing Feature
Leiomyoma is benign, homogeneously enhancing with low T2 signal; metastasis enhancement pattern varies by primary tumor and may be multiple. Leiomyoma grows very slowly; metastasis may grow rapidly. No systemic disease findings in leiomyoma.
Distinguishing Feature
Lymphoma shows diffuse concentric thickening with lumen preservation; metastasis shows focal eccentric mass or extrinsic compression. Very low ADC on DWI in lymphoma; ADC variable in metastasis. Very high FDG on PET in lymphoma; depends on primary tumor in metastasis.
Urgency
urgentManagement
medicalBiopsy
NeededFollow-up
specialist-referralEsophageal metastasis generally indicates advanced stage disease and prognosis depends on the primary tumor. Endoscopic biopsy is essential for diagnosis confirmation and primary tumor identification — immunohistochemistry helps determine primary source. Treatment is directed at primary tumor; palliative stenting or radiation therapy may be applied for symptomatic dysphagia. Surgical resection is rarely indicated. Whole-body staging with PET-CT determines disease extent. Targeted therapies (immunotherapy, TKI) may respond in melanoma, RCC, and thyroid metastases.
Esophageal metastasis generally indicates advanced disease. Treatment depends on primary tumor and overall condition. Palliative stenting can be performed for dysphagia. Prognosis is generally poor.